LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Suletud

SektorTervishoid

19.5 -1.02

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.5

Max

20.42

Põhinäitajad
By Trading Economics
Sissetulek	-1.6M -129M
Töötajad	503
EBITDA	8.9M -125M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+80.82% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-295M 3B
Eelmine avamishind	20.52
Eelmine sulgemishind	19.5

Uudiste sentiment

By Acuity

29%

71%

86 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. mai 2026, 23:55 UTC

Tulu

Review & Preview: Still Going Strong -- Barrons.com

8. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. mai 2026, 20:49 UTC

Tulu

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8. mai 2026, 20:25 UTC

Tulu

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8. mai 2026, 19:43 UTC

Tulu

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8. mai 2026, 19:43 UTC

Tulu

Cencosud 1Q Net $115M

8. mai 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8. mai 2026, 19:18 UTC

Tulu

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8. mai 2026, 19:16 UTC

Tulu

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8. mai 2026, 19:08 UTC

Tulu

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8. mai 2026, 19:05 UTC

Tulu

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8. mai 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8. mai 2026, 18:51 UTC

Tulu

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8. mai 2026, 18:49 UTC

Tulu

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8. mai 2026, 18:41 UTC

Tulu

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8. mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8. mai 2026, 17:14 UTC

Tulu

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8. mai 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. mai 2026, 15:39 UTC

Market Talk

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8. mai 2026, 15:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. mai 2026, 15:39 UTC

Market Talk

Canada's Job Market Sees Worst Start in Years -- Market Talk

8. mai 2026, 15:36 UTC

Market Talk

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8. mai 2026, 15:20 UTC

Market Talk

'Altcoin Season' Indicator on the Rise -- Market Talk

8. mai 2026, 15:20 UTC

Market Talk

Tulu

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8. mai 2026, 15:05 UTC

Market Talk

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8. mai 2026, 14:42 UTC

Market Talk

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8. mai 2026, 14:39 UTC

Market Talk

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

80.82% tõus

12 kuu keskmine prognoos

Keskmine 35.64 USD 80.82%

Kõrge 42 USD

Madal 23 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

86 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.